Background—Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective …

Rationale: Incident pulmonary arterial hypertension was underrepresented in most
pulmonary hypertension registries and may have a different disease profile to prevalent …

Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674
consecutive adult patients who were prospectively enrolled in the French PAH registry (121 …

The aim of the present study was to determine contemporary survival in pulmonary arterial
hypertension (PAH), and to investigate whether or not the National Institutes of Health (NIH) …

Idiopathic pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis.
New therapies have improved the outcome of this condition; accordingly, the factors that …

Idiopathic/heritable pulmonary arterial hypertension has a poor prognosis despite the
available therapeutic options. Survival of Japanese patients with this disease entity has not …

Rationale: The relationship between the initial treatment strategy and survival in pulmonary
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term …

Pulmonary Arterial Hypertension Without effective treatment, pulmonary arterial
hypertension results in high morbidity and mortality. This review discusses the pathogenesis …

likely responsible for most cases of PAH. The abnormal transduction of signals related to
BMPR2 and Alk/endoglin is unknown and needs aggressive investigation. This will involve …

For the first half of the twentieth century, the published reports on primary pulmonary
hypertension (PPH) were confined to clinical pathological correlations. In the 1950s the …